Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, ‘The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.’ It’s only natural to consider a company’s balance sheet when you examine how risky it is, since debt is often involved when a business collapses. We note that Metrovacesa S.A. (BME:MVC) does have debt on its balance sheet. But the real question is whether this debt is making the company risky.

Why Does Debt Bring Risk?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. When we examine debt levels, we first consider both cash and debt levels, together.

View our latest analysis for Metrovacesa

How Much Debt Does Metrovacesa Carry?

You can click the graphic below for the historical numbers, but it shows that as of June 2023 Metrovacesa had €412.5m of debt, an increase on €355.0m, over one year. On the flip side, it has €196.1m in cash leading to net debt of about €216.4m.

How Strong Is Metrovacesa’s Balance Sheet?

We can see from the most recent balance sheet that Metrovacesa had liabilities of €528.3m falling due within a year, and liabilities of €306.1m due beyond that. Offsetting this, it had €196.1m in cash and €31.3m in receivables that were due within 12 months. So its liabilities total €607.1m more than the combination of its cash and short-term receivables.

This deficit isn’t so bad because Metrovacesa is worth €1.20b, and thus could probably raise enough capital to shore up its balance sheet, if the need arose. But we definitely want to keep our eyes open to indications that its debt is bringing too much risk. There’s no doubt that we learn most about debt from the balance sheet. But it is future earnings, more than anything, that will determine Metrovacesa’s ability to maintain a healthy balance sheet going forward. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

It seems likely shareholders hope that Metrovacesa can significantly advance the business plan before too long, because it doesn’t have any significant revenue at the moment.

Caveat Emptor

Not only did Metrovacesa’s revenue slip over the last twelve months, but it also produced negative earnings before interest and tax (EBIT). To be specific the EBIT loss came in at €4.1m. When we look at that and recall the liabilities on its balance sheet, relative to cash, it seems unwise to us for the company to have any debt. So we think its balance sheet is a little strained, though not beyond repair. We would feel better if it turned its trailing twelve month loss of €71m into a profit. So in short it’s a really risky stock. When we look at a riskier company, we like to check how their profits (or losses) are trending over time. Today, we’re providing readers this interactive graph showing how Metrovacesa’s profit, revenue, and operating cashflow have changed over the last few years.

If you’re interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.